Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-0107-2026

FlexLab X (FXX) System. Potassium Test System. in vitro diagnostic Recall

FlexLab X (FXX) System. Potassium Test System. in vitro diagnostic

FDA recall Class II

Ongoing

FDA lists this Class II recall for FlexLab X (FXX) System. Potassium Test System. in vitro diagnostic. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-0107-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Sep 3, 2025
FDA report date
Oct 15, 2025
Quantity in commerce
1 unit
Distribution
See key details
FDA cause
No Marketing Application

What is being recalled?

FlexLab X (FXX) System. Potassium Test System. in vitro diagnostic

The retrieved code information does not contain explicit model/GTIN pairs that this publication can reliably map.

Search FDA identifier text

Search a model, catalog, lot or UDI value exactly as printed in FDA’s product description or code information.

This search checks only the FDA product description and code information displayed on this page. It does not decode a UDI, normalize GTIN lengths or establish a relationship between separately listed codes.

FDA code information

PN: FLX-056-40; UDI: 07640172344002: Serial No. FXX.0015.

View the original FDA recall notice

Why was this product recalled?

The FlexLab X System Sample Integrity Module (SIM) includes function that determines the hemolysis, icterus, and lipemia (HIL) in blood samples. This function has not been evaluated for safety and effectiveness by the FDA, so its use may cause an increase in erroneous results or a delay in patient results.

What actions did Inpeco S.A. take?

Consignees received an Urgent Medical Device Recall notification via email dated 9/3/25. The notification instructs consignees to not rely on HIL functionality for clinical decision making or to flag potentially erroneous samples. HIL functionality must be discontinued and cannot be disabled by users. Inspeco must send an Inspeco Servicer to consignee locations to disable HIL functionality. Inspeco will contact consingnees to schedule this service. Consignees are to forward the provided notification to those whom it might concern. Consignees with questions can contact Regulatory Affairs via email at regulatory.affairs@inspeco.com or Inspeco Service Team via email at service.NA@inspeco.com.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology